A multivalent chimeric vaccine composed of Schistosoma mansoni SmTSP-2 and Sm29 was able to induce protection against infection in mice

Parasite Immunology

Volumn 36, Issue 7, 2014, Pages 303-312

  Pinheiro, C S ^a,b   Ribeiro, A P D ^a   Cardoso, F C ^c   Martins, V P ^a,d,e   Figueiredo, B C P ^a,d   Assis, N R G ^a,d   Morais, S B ^a,d   Caliari, M V ^a   Loukas, A ^f   Oliveira, S C ^a,d  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d CNPq/MCT   (Brazil)

^e UNIVERSITY OF BRASILIA   (Brazil)

^f JAMES COOK UNIVERSITY   (Australia)

Author keywords

Schistosoma mansoni; Sm29; TSP 2; Vaccine

Indexed keywords

ADJUVANT; CHIMERIC PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 4; RECOMBINANT PROTEIN SM 29; RECOMBINANT PROTEIN SMTSP 2; SCHISTOSOMA VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMERA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HELMINTHIASIS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; INFECTION RESISTANCE; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; VACCINATION;

SCHISTOSOMA MANSONI; SM29; TSP-2; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, HELMINTH; ANTIGENS, BACTERIAL; ANTIGENS, HELMINTH; BACTERIAL PROTEINS; CPG ISLANDS; CYTOKINES; FEMALE; HELMINTH PROTEINS; HUMANS; IMMUNOGLOBULIN G; LIVER; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; RECOMBINANT PROTEINS; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; TETRASPANINS; VACCINES;

EID: 84902463492     PISSN: 01419838     EISSN: 13653024     Source Type: Journal    
DOI: 10.1111/pim.12118     Document Type: Article

References (36)

1. Gryseels B, Polman K, Clerinx J & Kestens L. Human schistosomiasis. Lancet 2006; 368: 1106-1118.
2. Steinmann P, Keiser J, Bos R, Tanner M & Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006; 6: 411-425.
3. Chitsulo L, Engels D, Montresor A & Savioli L. The global status of schistosomiasis and its control. Acta Trop 2000; 77: 41-51.
4. Wang LD, Chen HG, Guo JG, et al. A strategy to control transmission of Schistosoma japonicum in China. N Engl J Med 2009; 360: 121-128.
5. McManus DP & Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008; 21: 225-242.
6. Oliveira SC, Fonseca CT, Cardoso FC, Farias LP & Leite LC. Recent advances in vaccine research against schistosomiasis in Brazil. Acta Trop 2008; 108: 256-262.
7. McManus DP. Prospects for development of a transmission blocking vaccine against Schistosoma japonicum. Parasite Immunol 2005; 27: 297-308.
8. Smyth D, McManus DP, Smout MJ, Laha T, Zhang W & Loukas A. Isolation of cDNAs encoding secreted and transmembrane proteins from Schistosoma mansoni by a signal sequence trap method. Infect Immun 2003; 71: 2548-2554.
9. Tran MH, Pearson MS, Bethony JM, et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006; 12: 835-840.
10. Cardoso FC, Macedo GC, Gava E, et al. Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl Trop Dis 2008; 2: e308.
11. Romeih MH, Hassan HM, Shousha TS & Saber MA. Immunization against Egyptian Schistosoma mansoni infection by multivalent DNA vaccine. Acta Biochim Biophys Sin 2008; 40: 327-338.
12. Zhu L, Liu HF, Lu MB, Long QK, Shi YE & Yu LJ. Construction, purification, and evaluation of multivalent DNA vaccine against Schistosoma japonicum. Parasitol Res 2011; 108: 115-121.
13. Li C, Yu L, Liu Z, et al. Schistosoma japonicum: the design and experimental evaluation of a multivalent DNA vaccine. Cell Mol Biol Lett 2006; 11: 449-460.
14. Chen J, Liu H, Yang J & Chou KC. Prediction of linear B-cell epitopes using amino acid pair antigenicity scale. Amino Acids 2007; 33: 423-428.
15. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
16. Towbin H, Staehelin T & Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979; 76: 4350-4354.
17. Pacifico LG, Fonseca CT, Chiari L & Oliveira SC. Immunization with Schistosoma mansoni 22.6 kDa antigen induces partial protection against experimental infection in a recombinant protein form but not as DNA vaccine. Immunobiology 2006; 211: 97-104.
18. Fonseca CT, Brito CF, Alves JB & Oliveira SC. IL-12 enhances protective immunity in mice engendered by immunization with recombinant 14 kDa Schistosoma mansoni fatty acid-binding protein through an IFN-gamma and TNF-alpha dependent pathway. Vaccine 2004; 22: 503-510.
19. Cardoso LS, Araujo MI, Goes AM, Pacifico LG, Oliveira RR & Oliveira SC. Polymyxin B as inhibitor of LPS contamination of Schistosoma mansoni recombinant proteins in human cytokine analysis. Microb Cell Fact 2007; 6: 1.
20. Brito CF, Fonseca CT, Goes AM, Azevedo V, Simpson AJ & Oliveira SC. Human IgG1 and IgG3 recognition of Schistosoma mansoni 14 kDa fatty acid-binding recombinant protein. Parasite Immunol 2000; 22: 41-48.
21. Junqueira LC, Bignolas G & Brentani RR. Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J 1979; 11: 447-455.
22. Schneider MC, Aguilera XP, Barbosa da Silva Junior J, et al. Elimination of neglected diseases in latin America and the Caribbean: a mapping of selected diseases. PLoS Negl Trop Dis 2011; 5: e964.
23. Bergquist R. A century of schistosomiasis research. Acta Trop 2008; 108: 65-68.
24. Bergquist NR. Schistosomiasis vaccine development: approaches and prospects. Mem Inst Oswaldo Cruz 1995; 90: 221-227.
25. Gray DJ, McManus DP, Li Y, Williams GM, Bergquist R & Ross AG. Schistosomiasis elimination: lessons from the past guide the future. Lancet Infect Dis 2010; 10: 733-736.
26. Chitsulo L, Loverde P & Engels D. Schistosomiasis. Nat Rev Microbiol 2004; 2: 12-13.
27. Bergquist R, Utzinger J & McManus DP. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis 2008; 2: e244.
28. Loukas A, Tran M & Pearson MS. Schistosome membrane proteins as vaccines. Int J Parasitol 2007; 37: 257-263.
29. Pinheiro CS, Martins VP, Assis NR, et al. Computational vaccinology: an important strategy to discover new potential S. mansoni vaccine candidates. J Biomed Biotechnol 2011; 2011: 503068.
30. Pearson MS, Pickering DA, McSorley HJ, et al. Enhanced protective efficacy of a chimeric form of the schistosomiasis vaccine antigen Sm-TSP-2. PLoS Negl Trop Dis 2012; 6: e1564.
31. Martins VP, Pinheiro CS, Figueiredo BC, et al. Vaccination with enzymatically cleaved GPI-anchored proteins from Schistosoma mansoni induces protection against challenge infection. Clin Dev Immunol 2012; 2012: 962538.
32. Hewitson JP, Hamblin PA & Mountford AP. Immunity induced by the radiation-attenuated schistosome vaccine. Parasite Immunol 2005; 27: 271-280.
33. Smythies LE, Coulson PS & Wilson RA. Monoclonal antibody to IFN-gamma modifies pulmonary inflammatory responses and abrogates immunity to Schistosoma mansoni in mice vaccinated with attenuated cercariae. J Immunol 1992; 149: 3654-3658.
34. Pinho JM, Cardoso FC, Lopes DO, et al. Immunization with SmIg, a novel tegument protein from Schistosoma mansoni, fails to induce protection in mice but reduces liver pathology. Parasitology 2010; 137: 1079-1088.
35. Garcia TC, Fonseca CT, Pacifico LG, et al. Peptides containing T cell epitopes, derived from Sm14, but not from paramyosin, induce a Th1 type of immune response, reduction in liver pathology and partial protection against Schistosoma mansoni infection in mice. Acta Trop 2008; 106: 162-167.
36. Cardoso FC, Pacifico RN, Mortara RA & Oliveira SC. Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies. Clin Exp Immunol 2006; 144: 382-391.